Skip to main content
. 2020 Oct 24;19:186. doi: 10.1186/s12933-020-01161-x

Table 2.

Concomitant medication usage during the treatment period by baseline serum alkaline phosphatase quartiles

Variables* Baseline serum alkaline phosphatase quartiles, IU/L P value
Q1 (< 79) Q2 (79- < 96) Q3 (96- < 116) Q4 (≥ 116)
N 3486 3623 3577 3707
Antihypertensive drugs
 Calcium channel blockers 2804 (80.4) 2954 (81.5) 2958 (82.7) 3110 (83.9)  < 0.001
 Diuretics 2011 (57.7) 2028 (56.0) 1901 (53.1) 1750 (47.2)  < 0.001
Lipid-lowering drugs 5 (0.1) 3 (0.1) 6 (0.2) 5 (0.1) 0.790
Antiplatelet drugs 33 (0.9) 35 (1.0) 26 (0.7) 17 (0.5) 0.045

*Regular concomitant medication usage was defined as 180 or more cumulative days of taking the drug of interest

Difference between any 2 groups